You are here

FASEB J DOI:10.1096/fj.201700028

The Path to New Therapies for Schizophrenia and Bipolar Illness.

Publication TypeJournal Article
Year of Publication2017
AuthorsScolnick, EM
JournalFASEB J
Volume31
Issue4
Pages1254-1259
Date Published2017 04
ISSN1530-6860
KeywordsAntipsychotic Agents, Genetic Predisposition to Disease, Genome, Human, Humans, Molecular Targeted Therapy, Schizophrenia
Abstract

Schizophrenia and bipolar illness are two of the most serious forms of mental illness. Until relatively recently, almost nothing was known about the molecular pathogenesis of either illness. The single largest risk factor that predisposes people to schizophrenia or bipolar illness is genetic risk. Heritability is high, and the incidence is significantly higher in identical twins than in nonidentical twins. Despite decades of work aimed at identifying the genes involved in these two illnesses, virtually no progress had been made until the past decade. With the knowledge and technologies that have been gained from the Human Genome Project, it has been possible to begin to understand the underlying genetics and to use the new information to begin the effort to discover new and better medicines to treat these illnesses. This article will describe the past decade of work toward this goal and articulate both the promise that now exists and what is still needed to bring dramatic and tangible change to patients.-Scolnick, E. M. The path to new therapies for schizophrenia and bipolar illness.

DOI10.1096/fj.201700028
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/28360375?dopt=Abstract

Alternate JournalFASEB J.
PubMed ID28360375
Additional Materials